Tag: Cytokine storm

According to a study published in *Nature*, approximately 13.5% of patients who discontinued ruxolitinib (Jakafi) experienced a withdrawal syndrome. If you stop Jakafi abruptly, you risk triggering a life-threatening rebound of your underlying disease and a systemic inflammatory response, highlighting the critical need for medical supervision.

Up to 13.5% of patients who discontinue ruxolitinib may experience withdrawal symptoms, highlighting the importance of understanding **what are the withdrawal symptoms of ruxolitinib** and the risks of abrupt cessation. This potentially life-threatening rebound of inflammatory cytokines is known as Ruxolitinib Discontinuation Syndrome (RDS).

According to the World Health Organization, corticosteroids like prednisone are recommended for patients with severe or critical COVID-19 who require supplemental oxygen. This is because prednisone works to suppress the hyperinflammatory immune response, known as a "cytokine storm," which can cause severe lung damage and organ failure in advanced cases.

Multiple clinical trials, including the landmark RECOVERY trial, showed that deaths were reduced by one-third for hospitalized COVID-19 patients on ventilators when treated with dexamethasone. This potent synthetic corticosteroid offers a crucial **life saving benefit of dexamethasone** by mitigating the body's overactive immune response, which can cause more harm than the underlying disease.